Etiology spectrum， clinical features， and gene mutations of unexplained intrahepatic cholestasis： An analysis of 62 cases

Jialuo WANG; Yufeng ZHENG; Qingfang XIONG; Yongfeng YANG

doi:10.12449/JCH250217

Volume 41 Issue 2

Feb. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(2): 307-313

PDF( 1558 KB)

Etiology spectrum， clinical features， and gene mutations of unexplained intrahepatic cholestasis： An analysis of 62 cases

DOI: 10.12449/JCH250217

Department of Infectious Diseases and Liver Diseases，Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital，Nanjing 210003，China

Research funding:

National Natural Science Foundation of China (81970454);

The Graduate Research and Practice Innovation Program Project of Jiangsu Province (KYCX24_2180)

More Information

Corresponding author: YANG Yongfeng， yangyongfeng@njucm.edu.cn （ORCID： 0000-0002-0942-4833）
Received Date: 2024-07-09
Accepted Date: 2024-09-23
Published Date: 2025-02-25

Abstract

Abstract

Objective To investigate the etiology and clinical features of intrahepatic cholestasis and the diagnostic value of whole exome sequencing （WES） through a retrospective analysis of the medical history， pathological results， and gene sequencing data of 62 patients with unexplained intrahepatic cholestasis. Methods A retrospective analysis was performed for the clinical data of 480 patients who underwent WES due to unexplained liver function abnormalities in Nanjing Second Hospital from January 2017 to December 2023， among whom 62 patients with unexplained intrahepatic cholestasis were selected based on laboratory data， and a confirmed diagnosis was made based on imaging data， pathological findings， and gene sequencing data. The patients with unexplained intrahepatic cholestasis were analyzed in terms of demographic features， clinical manifestation， etiology spectrum， and genetic profile. Results A total of 62 patients with unexplained intrahepatic cholestasis were included， among whom there were 35 male patients and 27 female patients， with a median age of 42 （7 — ‍77） years. WES was used to make a definite diagnosis in 21 patients （33.87%）， among whom the patients with familial intrahepatic cholestasis accounted for the highest proportion of 52.38% （11/21）； genetic metabolic disorders were excluded by WES in 34 patients， with drug-induced liver injury and sepsis-associated liver injury accounting for the highest proportion of 55.88% （19/34）， followed by primary biliary cholangitis and primary sclerosing cholangitis accounting for 20.59% （7/34） and intrahepatic bile duct stones accounting for 17.65% （6/34）， while the patients with a lack of confirmed diagnosis accounted for 11.29% （7/62）. A total of 21 novel mutation sites which were not reported in previous articles were identified in this study. Conclusion Genetic metabolic disorders constitute a significant proportion of unexplained intrahepatic cholestasis， and WES plays a crucial role in the diagnosis of unexplained intrahepatic cholestasis.
- Liver Diseases,
- Cholestasis， Intrahepatic,
- Diagnosis,
- Mutation

FullText(HTML)

References(28)

References

[1]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of cholestasis liver diseases(2021)[J]. J Clin Hepatol, 2022, 38( 1): 62- 69. DOI: 10.3969/j.issn.1001-5256.2022.01.010. 中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 62- 69. DOI: 10.3969/j.issn.1001-5256.2022.01.010.
[2]	BORTOLINI M, ALMASIO P, BRAY G, et al. Multicentre survey of the prevalence of intrahepatic cholestasis in 2520 consecutive patients with newly diagnosed chronic liver disease[J]. Drug Investig, 1992, 4( 4): 83- 89. DOI: 10.1007/BF03258368.
[3]	NG SB, BUCKINGHAM KJ, LEE C, et al. Exome sequencing identifies the cause of a Mendelian disorder[J]. Nat Genet, 2010, 42( 1): 30- 35. DOI: 10.1038/ng.499.
[4]	BOTSTEIN D, RISCH N. Discovering genotypes underlying human phenotypes: Past successes for Mendelian disease, future approaches for complex disease[J]. Nat Genet, 2003, 33 Suppl: 228- 237. DOI: 10.1038/ng1090.
[5]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51( 2): 237- 267. DOI: 10.1016/j.jhep.2009.04.009.
[6]	GUNAYDIN M, BOZKURTER CIL AT. Progressive familial intrahepatic cholestasis: Diagnosis, management, and treatment[J]. Hepat Med, 2018, 10: 95- 104. DOI: 10.2147/HMER.S137209.
[7]	GUO J, XIE SY, YANG LR, et al. Clinical characteristics of 2 cases of progressive familial intrahepatic cholestasis and literature review[J/CD]. Chin J Liver Dis(Electronic Version), 2024, 16( 1): 67- 72. DOI: 10.3969/j.issn.1674-7380.2024.01.012. 郭静, 谢双宇, 杨玲蓉, 等. 进行性家族性肝内胆汁淤积症2例临床特点分析及文献复习[J/CD]. 中国肝脏病杂志(电子版), 2024, 16( 1): 67- 72. DOI: 10.3969/j.issn.1674-7380.2024.01.012.
[8]	WENG YH, XIONG QF, LIU DX, et al. Clinical and pathological features of progressive familial intrahepatic cholestasis type 3[J]. J Clin Hepatol, 2022, 38( 1): 154- 159. DOI: 10.3969/j.issn.1001-5256.2022.01.024. 翁宇航, 熊清芳, 刘杜先, 等. 进行性家族性肝内胆汁淤积症3型临床病理特征分析[J]. 临床肝胆病杂志, 2022, 38( 1): 154- 159. DOI: 10.3969/j.issn.1001-5256.2022.01.024.
[9]	GOTTHARDT D, RUNZ H, KEITEL V, et al. A mutation in the canalicular phospholipid transporter gene, ABCB4 is associated with cholestasis, ductopenia, and cirrhosis in adults[J]. Hepatology, 2008, 48( 4): 1157- 1166. DOI: 10.1002/hep.22485.
[10]	HALAWI A, IBRAHIM N, BITAR R. Triggers of benign recurrent intrahepatic cholestasis and its pathophysiology: A review of literature[J]. Acta Gastroenterol Belg, 2021, 84( 3): 477- 486. DOI: 10.51821/84.3.013.
[11]	CHEN FF, PENG LQ, WANG J. Correlation between serum glycocholic acid and liver biochemical indexes and inflammatory cytokines in patients with intrahepatic chole-stasis of pregnancy[J]. J Clin Exp Med, 2023, 22( 14): 1534- 1537. DOI: 10.3969/j.issn.1671-4695.2023.14.021. 陈福芳, 彭丽钦, 汪洁. 妊娠期肝内胆汁淤积症患者血清甘胆酸与肝生化指标、炎性细胞因子水平变化相关性分析[J]. 临床和实验医学杂志, 2023, 22( 14): 1534- 1537. DOI: 10.3969/j.issn.1671-4695.2023.14.021.
[12]	Obstetrics Subgroup, Society of Obstetrics and Gynecology, Chinese Medical Association; Society of Perinatal Medicine, Chinese Medical Association. Guidelines for clinical diagnosis, treatment and management of intrahepatic cholestasis of pregnancy(2024)[J]. Chin J Obstet Gynecol, 2024, 59( 2): 97- 107. DOI: 10.3760/cma.j.cn112141-20230914-00099. 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 妊娠期肝内胆汁淤积症临床诊治和管理指南(2024版)[J]. 中华妇产科杂志, 2024, 59( 2): 97- 107. DOI: 10.3760/cma.j.cn112141-20230914-00099.
[13]	AYDıN GA, ÖZGEN G, GÖRÜKMEZ O. The role of genetic mutations in intrahepatic cholestasis of pregnancy[J]. Taiwan J Obstet Gynecol, 2020, 59( 5): 706- 710. DOI: 10.1016/j.tjog.2020.07.014.
[14]	NAYAGAM JS, WILLIAMSON C, JOSHI D, et al. Review article: Liver disease in adults with variants in the cholestasis-related genes ABCB11 ABCB4 and ATP8B1[J]. Aliment Pharmacol Ther, 2020, 52( 11-12): 1628- 1639. DOI: 10.1111/apt.16118.
[15]	AYOUB MD, KAMATH BM. Alagille syndrome: Current understanding of pathogenesis, and challenges in diagnosis and management[J]. Clin Liver Dis, 2022, 26( 3): 355- 370. DOI: 10.1016/j.cld.2022.03.002.
[16]	LI LT, DONG JB, WANG XH, et al. JAG1 mutation spectrum and origin in Chinese children with clinical features of alagille syndrome[J]. PLoS One, 2015, 10( 6): e0130355. DOI: 10.1371/journal.pone.0130355.
[17]	Inherited Metabolic Liver Disease Collaboration Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the diagnosis and treatment of hepatolenticular degeneration(2022 edition)[J]. Chin J Hepatol, 2022, 30( 1): 9- 20. DOI: 10.3760/cma.j.cn501113-20211217-00603. 中华医学会肝病学分会遗传代谢性肝病协作组. 肝豆状核变性诊疗指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30( 1): 9- 20. DOI: 10.3760/cma.j.cn501113-20211217-00603.
[18]	DANKS DM. Copper and liver disease[J]. Eur J Pediatr, 1991, 150( 3): 142- 148. DOI: 10.1007/BF01963553.
[19]	HASBAOUI BE, RIFAI Z, SAGHIR S, et al. Congenital hepatic fibrosis: Case report and review of literature[J]. Pan Afr Med J, 2021, 38: 188. DOI: 10.11604/pamj.2021.38.188.27941.
[20]	Writing Group For Practice Guidelines For Diagnosis And Treatment Of Genetic Diseases Medical Genetics Branch Of Chinese Medical Association. Clinical practice guidelines for polycystic kidney diseases[J]. Chin J Med Genet, 2020, 37( 3): 277- 283. DOI: 10.3760/cma.j.issn.1003-9406.2020.03.009. 中华医学会医学遗传学分会遗传病临床实践指南撰写组. 多囊肾病的临床实践指南[J]. 中华医学遗传学杂志, 2020, 37( 3): 277- 283. DOI: 10.3760/cma.j.issn.1003-9406.2020.03.009.
[21]	KARHUNEN PJ, TENHU M. Adult polycystic liver and kidney diseases are separate entities[J]. Clin Genet, 1986, 30( 1): 29- 37. DOI: 10.1111/j.1399-0004.1986.tb00565.x.
[22]	LANKTREE MB, HAGHIGHI A, di BARI I, et al. Insights into autosomal dominant polycystic kidney disease from genetic studies[J]. Clin J Am Soc Nephrol, 2021, 16( 5): 790- 799. DOI: 10.2215/CJN.02320220.
[23]	DIXIT A, PATEL C, HARRISON R, et al. 17q12 microdeletion syndrome: Three patients illustrating the phenotypic spectrum[J]. Am J Med Genet A, 2012, 158 A( 9): 2317- 2321. DOI: 10.1002/ajmg.a.35520.
[24]	Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176. 中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
[25]	Biliary Surgery Group of the Surgery Branch of the Chinese Medical Association. Guidelines for diagnosis and treatment of hepatolithiasis[J]. Chin J Dig Surg, 2007, 6( 2): 156- 161. DOI: 10.3760/cma.j.issn.1673-9752.2007.02.028. 中华医学会外科学分会胆道外科学组. 肝胆管结石病诊断治疗指南[J]. 中华消化外科杂志, 2007, 6( 2): 156- 161. DOI: 10.3760/cma.j.issn.1673-9752.2007.02.028.
[26]	YAO X, LIU Y, YU LD, et al. Rare portal hypertension caused by abernethy malformation(type IIC): A case report[J]. World J Radiol, 2023, 15( 8): 250- 255. DOI: 10.4329/wjr.v15.i8.250.
[27]	ENNAIFER R, BACHA D, ROMDHANE H, et al. Budd-chiari syndrome: An unusual presentation of multisystemic sarcoidosis[J]. Clin Pract, 2015, 5( 3): 768. DOI: 10.4081/cp.2015.768.
[28]	WOJCIK MH, LEMIRE G, BERGER E, et al. Genome sequencing for diagnosing rare diseases[J]. N Engl J Med, 2024, 390( 21): 1985- 1997. DOI: 10.1056/NEJMoa2314761.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (2644) PDF downloads(87)

Etiology spectrum， clinical features， and gene mutations of unexplained intrahepatic cholestasis： An analysis of 62 cases

DOI: 10.12449/JCH250217

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Etiology spectrum， clinical features， and gene mutations of unexplained intrahepatic cholestasis： An analysis of 62 cases

DOI: 10.12449/JCH250217

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content